Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Loss of Beta-Cell EPAC2A Activity Linked to Development of Type II Diabetes

By BiotechDaily International staff writers
Posted on 25 Apr 2013
Print article
Diabetes researchers have discovered how the protein EPAC2A (guanine nucleotide exchange factors for Ras-like small GTPases) affects glucose metabolism and how loss of this protein activity may contribute to the development of type II diabetes.

Incretin hormone action on beta cells stimulates in parallel two different intracellular cyclic AMP-dependent signaling branches mediated by PKA (protein kinase A) and EPAC2A. Both pathways contribute towards potentiation of glucose-stimulated insulin secretion. However, the overall functional role of EPAC2A in beta cells as it relates to in vivo glucose homeostasis has not been well understood.

Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta-cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. Furthermore, they also inhibit glucagon release from the alpha cells of the islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP).

In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) examined the interaction between incretins and EPAC2A. To do this they genetically engineered a line of mice lacking the gene for EPAC2A production.

Results published in the April 11, 2013, online edition of the journal Diabetes revealed that EPAC2A deficiency did not impact glucose-stimulated insulin secretion in the knockout mice under normal conditions. However, when the mice were exposed to diet-induced insulin resistance or incretin hormone stimulation of beta cells, EPAC2A was required for the increased beta-cell response to secretory demand. Under these circumstances, EPAC2A was required for potentiating the early dynamic increase in islet calcium levels after glucose stimulation, which is reflected in potentiated first phase insulin secretion.

“It is as if during these extreme conditions, the body calls upon EPAC2 as backup to help it balance insulin supply and demand,” said senior author Dr. Mehboob Hussain, associate professor of pediatrics, medicine, and biological chemistry at Johns Hopkins University. “Drugs that precision-target failing pancreatic cells and restore or boost their function have become the holy grail of diabetes research. We believe that our finding establishes a pathway to do just that.”

Related Links:
Johns Hopkins University


Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.